Former Chief Operating Officer and Chief Financial Officer · PMV Pharmaceuticals, Inc. (PMVP)

Winston Kung

A named executive officer of PMV Pharmaceuticals in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,260,259

Salary $475,299Stock awards $0

FY2022: $1,768,476

2nd of 3 named executive officers at PMV Pharmaceuticals by FY2023 total.

3 named officers on file for PMV Pharmaceuticals, FY2023

Winston Kung’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • PMVP’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how PMV Pharmaceuticals’s whole pay program stands against its peers

  • PMV Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PMVP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2024 (DEF 14A).

Free

Get Winston Kung’s full pay file as a PDF — free

More than this page: up to 10 years of Winston’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Winston Kung compensation by year

PMV Pharmaceuticals Summary Compensation Table · all 5 fiscal years held
In US dollars, as PMV Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$410,000$427,535$448,017$461,455$475,299
Bonus$0$0$0$0$0
Stock awards$0$0$0$0$0
Option awards$0$216,433$992,142$1,177,183$603,960
Non-equity incentive$152,440$181,397$225,100$129,838$181,000
Pension and deferred compensation$0$0$0$0$0
All other$0$0$0$0$0
Total$562,440$825,365$1,665,259$1,768,476$1,260,259

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PMV Pharmaceuticals, Inc. DEF 14A filed April 24, 2024, accession 0001140361-24-021596, and prior-year filings. Open the filing on EDGAR.

How this page was built: the PMV Pharmaceuticals, Inc. filed document, accession 0001140361-24-021596. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2024.

$562K
$825K
$1.7M
$1.8M
$1.3M
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option5,472—$3.90
Option17,828—$28.33
Option281,875—$5.70
Option56,550—$16.29
Option23,315—$3.22

Per the Outstanding Equity Awards at Fiscal Year-End table in PMV Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

PMV Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
David MackPresident, Chief Executive Officer and Director$2,209,795
Winston Kung · this pageFormer Chief Operating Officer and Chief Financial Officer$1,260,259
Deepika JalotaChief Development Officer$1,097,198

The full PMV Pharmaceuticals compensation record

free company brief

This page is one person within PMV Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the PMV Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PMV Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Winston Kung's compensation dossier · One-time report. No refunds.